Platelet-Derived Growth Factor Inhibitors: A Potential Therapeutic Approach for Ocular Neovascularization.

Developments in ophthalmology Pub Date : 2016-01-01 Epub Date: 2015-10-26 DOI:10.1159/000438953

Mohammad Ali Sadiq, Mostafa Hanout, Salman Sarwar, Muhammad Hassan, Aniruddha Agarwal, Yasir Jamal Sepah, Diana V Do, Quan Dong Nguyen

{"title":"Platelet-Derived Growth Factor Inhibitors: A Potential Therapeutic Approach for Ocular Neovascularization.","authors":"Mohammad Ali Sadiq, Mostafa Hanout, Salman Sarwar, Muhammad Hassan, Aniruddha Agarwal, Yasir Jamal Sepah, Diana V Do, Quan Dong Nguyen","doi":"10.1159/000438953","DOIUrl":null,"url":null,"abstract":"<p><p>Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factors (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF play an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly neovascular AMD, has become more exciting due to agents like PDGF antagonists.</p>","PeriodicalId":77107,"journal":{"name":"Developments in ophthalmology","volume":"55 ","pages":"310-6"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000438953","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Developments in ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000438953","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/10/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factors (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF play an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly neovascular AMD, has become more exciting due to agents like PDGF antagonists.

查看原文本刊更多论文

血小板衍生生长因子抑制剂:一种治疗眼部新生血管的潜在方法。

视网膜脉络膜血管疾病是发达国家致盲的主要原因。它们包括糖尿病视网膜病变、视网膜静脉闭塞、早产儿视网膜病变、年龄相关性黄斑变性(AMD)和病理性近视等。目前正在考虑几种不同的治疗上述疾病的方法。在下一节中，针对血小板衍生生长因子(PDGF)的药物作为视网膜脉络膜血管疾病的潜在治疗选择进行了讨论。PDGF在视网膜脉络膜血管疾病中激活的血管生成级联反应中起重要作用。讨论了这些药物与其他治疗方案联合的作用机制、副作用、疗效和潜在的协同作用。由于PDGF拮抗剂等药物的出现，视网膜脉络膜血管性疾病，特别是新血管性AMD的治疗前景变得更加令人兴奋。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Developments in ophthalmology

自引率

0.00%

发文量